Prognostic implications of immunohistochemically detected YKL-40 expression in breast cancer

World Journal of Surgical Oncology

Volumn 5, Issue , 2007, Pages

  Kim, Steve H ^a   Das, Kasturi ^a   Noreen, Shahla ^a   Coffman, Frederick ^a   Hameed, Meera ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COLLAGEN; ESTROGEN RECEPTOR; GLYCOPROTEIN GP 39; PROGESTERONE RECEPTOR; CHI3L1 PROTEIN, HUMAN; GLYCOPROTEIN; TUMOR MARKER;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA BASE; DISEASE FREE SURVIVAL; EXTRACELLULAR MATRIX; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MASTECTOMY; MITOGENESIS; MULTIVARIATE ANALYSIS; PREDICTION; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION; TUMOR VOLUME; UNITED STATES; UNIVERSITY HOSPITAL; AGED; BLOOD; BREAST TUMOR; CANCER INVASION; COHORT ANALYSIS; COMPARATIVE STUDY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METHODOLOGY; MIDDLE AGED; MORTALITY; NEEDLE BIOPSY; PATHOLOGY; PROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; SURVIVAL;

ADULT; AGED; BIOPSY, NEEDLE; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33847660092     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-5-17     Document Type: Article

References (34)

1. Johansen JS Williamson MK Rice JS Price PA Identification of proteins secreted by human osteoblastic cells in culture J Bone Miner Res 1992 7 501-512 1615759
2. Badariotti F Kypriotou M Lelong C Dubos MP Renard E Galera P Favrel P The phylogenetically conserved molluscan Chitinase-like protein 1 (Cg-Clp1), homologue of human HC-gp39, stimulates proliferation and regulates synthesis of extracellular matrix components of mammalian chondrocytes J Biol Chem 2006 281 29583-29596 10.1074/jbc.M605687200 16882657
3. Rathcke CN Vestergaard H YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis Inflamm Res 2006 55 221-227 10.1007/s00011-006-0076-y 16955240
4. Johansen JS Jensen HS Price PA A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid Br J Rheumatol 1993 32 949-955 10.1093/rheumatology/32.11.949 8220933
5. Johansen JS Krabbe KS Moller K Pedersen BK Circulating YKL-40 levels during human endotoxaemia Clin Exp Immunol 2005 140 343-348 10.1111/ j.1365-2249.2005.02763.x 15807860
6. Johansen JS Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer Dan Med Bull 2006 53 172-209 17087877
7. De Ceuninck F Gaufillier S Bonnaud A Sabatini M Lesur C Pastoureau P YKL-40 (cartilage gp-39) induces proliferative events in cultured chondrocytes and synoviocytes and increases glycosaminoglycan synthesis in chondrocytes Biochem Biophys Res Commun 2001 285 926-931 10.1006/ bbrc.2001.5253 11467840
8. Schmidt H Johansen JS Gehl J Geertsen PF Fode K von der Maase H Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma Cancer 2006 106 1130-1139 10.1002/cncr.21678 16456816
9. Schmidt H Johansen JS Sjoegren P Christensen IJ Sorensen BS Fode K Larsen J von der Maase H Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma J Clin Oncol 2006 24 798-804 10.1200/JCO.2005.03.7960 16391295
10. Pelloski CE Mahajan A Maor M Chang EL Woo S Gilbert M Colman H Yang H Ledoux A Blair H Passe S Jenkins RB Aldape KD YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma Clin Cancer Res 2005 11 3326-3334 10.1158/ 1078-0432.CCR-04-1765 15867231
11. Johansen JS Christensen IJ Riisbro R Greenall M Han C Price PA Smith K Brunner N Harris AL High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival Breast Cancer Res Treat 2003 80 15-21 10.1023/A:1024431000710 12889595
12. Johansen JS Cintin C Jorgensen M Kamby C Price PA Serum YKL-40: A new potential marker of prognosis and location of metastases of patients with recurrent breast cancer Eur J Cancer 1995 31A 1437-1442 10.1016/ 0959-8049(95)00196-P 7577068
13. Johansen JS Drivsholm L Price PA Christensen IJ High serum YKL-40 level in patients with small cell lung cancer is related to early death Lung Cancer 2004 46 333-340 10.1016/j.lungcan.2004.05.010 15541818
14. Jensen BV Johansen JS Price PA High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer Clin Cancer Res 2003 9 4423-4434 14555515
15. Dehn H Hogdall EV Johansen JS Jorgensen M Price PA Engelholm SA Hogdall CK Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer Acta Obstet Gynecol Scand 2003 82 287-293 10.1034/ j.1600-0412.2003.00010.x 12694127
16. Dupont J Tanwar MK Thaler HT Fleisher M Kauff N Hensley ML Sabbatini P Anderson S Aghajanian C Holland EC Spriggs DR Early detection and prognosis of ovarian cancer using serum YKL-40 J Clin Oncol 2004 22 3330-3339 10.1200/JCO.2004.09.112 15310777
17. Hogdall EV Johansen JS Kjaer SK Price PA Christensen L Blaakaer J Bock JE Glud E Hogdall CK High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival Oncol Rep 2003 10 1535-1538 12883737
18. Brasso K Christensen IJ Johansen JS Teisner B Garnero P Price PA Iversen P Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma Prostate 2006 66 503-513 10.1002/pros.20311 16372331
19. Cintin C Johansen JS Christensen IJ Price PA Sorensen S Nielsen HJ Serum YKL-40 and colorectal cancer Br J Cancer 1999 79 1494-1499 10.1038/ sj.bjc.6690238 10188896
20. Cintin C Johansen JS Christensen IJ Price PA Sorensen S Nielsen HJ High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival Cancer 2002 95 267-274 10.1002/cncr.10644 12124825
21. Bergmann OJ Johansen JS Klausen TW Mylin AK Kristensen JS Kjeldsen E Johnsen HE High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia Clin Cancer Res 2005 11 24 Pt 1 8644 8652 10.1158/1078-0432.CCR-05-1317 16361549
22. Jemal A Siegel R Ward E Murray T Xu J Smigal C Thun MJ Cancer statistics, 2006 CA Cancer J Clin 2006 56 106-130 16514137
23. Cooke T Reeves J Lanigan A Stanton P HER2 as a prognostic and predictive marker for breast cancer Ann Oncol 2001 12 Suppl 1 S23 S28 10.1023/ A:1011159723172 11521717
24. Valagussa P HER2 status: A statistician's view Ann Oncol 2001 12 Suppl 1 S29 S34 10.1023/A:1011111807242 11521718
25. Piccart-Gebhart MJ Procter M Leyland-Jones B Goldhirsch A Untch M Smith I Gianni L Baselga J Bell R Jackisch C Cameron D Dowsett M Barrios CH Steger G Huang CS Andersson M Inbar M Lichinitser M Lang I Nitz U Iwata H Thomssen C Lohrisch C Suter TM Ruschoff J Suto T Greatorex V Ward C Straehle C McFadden E Dolci MS Gelber RD Herceptin Adjuvant (HERA) Trial Study Team Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 2005 353 1659-1672 10.1056/NEJMoa052306 16236737
26. Romond EH Perez EA Bryant J Suman VJ Geyer CE Jr Davidson NE Tan-Chiu E Martino S Paik S Kaufman PA Swain SM Pisansky TM Fehrenbacher L Kutteh LA Vogel VG Visscher DW Yothers G Jenkins RB Brown AM Dakhil SR Mamounas EP Lingle WL Klein PM Ingle JN Wolmark N Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 2005 353 1673-1684 10.1056/NEJMoa052122 16236738
27. Slamon DJ Leyland-Jones B Shak S Fuchs H Paton V Bajamonde A Fleming T Eiermann W Wolter J Pegram M Baselga J Norton L Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 2001 344 783-792 10.1056/ NEJM200103153441101 11248153
28. Paik S Shak S Tang G Kim C Baker J Cronin M Baehner FL Walker MG Watson D Park T Hiller W Fisher ER Wickerham DL Bryant J Wolmark N A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 2004 351 2817-2826 10.1056/NEJMoa041588 15591335
29. van de Vijver MJ He YD van't Veer LJ Dai H Hart AA Voskuil DW Schreiber GJ Peterse JL Roberts C Marton MJ Parrish M Atsma D Witteveen A Glas A Delahaye L van der Velde T Bartelink H Rodenhuis S Rutgers ET Friend SH Bernards R A gene-expression signature as a predictor of survival in breast cancer N Engl J Med 2002 347 1999-2009 10.1056/NEJMoa021967 12490681
30. Roslind A Johansen JS Junker N Nielsen DL Bentzon N Price PA Balslev E YKL-40 expression in breast cancer J Clin Oncol 2005 23 16S, June 1 supplement, 2005 ASCO AnnualMeeting Proceedings 9665 http://www.asco.org/portal/site/ASCO/ menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid= 76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview= abst_detail_view&confID=34&index=y&abstractID=30515
31. Johnson CH SEER Program Coding and Staging Manual Bethesda, MD: National Cancer Institute, NIH 2004
32. Kaplan E Meier P Nonparametric estimation from incomplete observations J Am Statist 1958 53 457-481 10.2307/2281868
33. Newman LA Mason J Cote D Vin Y Carolin K Bouwman D Colditz GA African-American ethnicity, socioeconomic status, and breast cancer survival: A meta-analysis of 14 studies involving over 10,000 African-American and 40,000 White American patients with carcinoma of the breast Cancer 2002 94 2844-2854 10.1002/cncr.10575 12115371
34. Jatoi I Becher H Leake CR Widening disparity in survival between white and African-American patients with breast carcinoma treated in the U. S. Department of Defense Healthcare system Cancer 2003 98 894-899 10.1002/ cncr.11604 12942554